株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

アルテミシニン併用療法(ACT)- 世界市場の見通し(2017年〜2026年)

Artemisinin Combination - Global Market Outlook (2017-2026)

発行 Stratistics Market Research Consulting 商品コード 755121
出版日 ページ情報 英文 175 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
アルテミシニン併用療法(ACT)- 世界市場の見通し(2017年〜2026年) Artemisinin Combination - Global Market Outlook (2017-2026)
出版日: 2018年11月01日 ページ情報: 英文 175 Pages
概要

世界のアルテミシニン併用療法(ACT)市場は、2017年に3,388億米ドルと評価され、2017年から2026年には10.5%のCAGRで推移し、2026年までに8,309億8,000万米ドル規模の市場に成長することが予測されています。新たな抗マラリア薬の登場や、アルテミシニン併用療法(ACT)の需要の増加、政府によるイニシアチブなどが当市場の主な成長要因となっています。

当レポートでは、世界のアルテミシニン併用療法(ACT)市場を調査し、市場の概要、タイプ・地域別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 市場動向の分析

  • イントロダクション
  • 成長要因
  • 阻害要因
  • 市場機会
  • 脅威
  • 新興市場
  • 今後の市場のシナリオ

第4章 ファイブフォース分析

  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係

第5章 世界のアルテミシニン併用療法(ACT)市場:タイプ別

  • イントロダクション
  • アルテスネート+スルファドキシン+ピリメタミン併用
  • アルテスネート+メフロキン併用
  • アルテスネート+ピロナリジン併用
  • アルテスネート+ルメファントリン併用
  • アルテスネート+アモジアキン併用
  • ジヒドロアルテミシニン+ピペラキン併用

第6章 世界のアルテミシニン併用療法(ACT)市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他

第7章 市場の主な動向

  • 合意、パートナーシップ、コラボレーション、合弁事業
  • 買収と合併
  • 新製品の発売
  • 拡張
  • その他の主要戦略

第8章 企業プロファイル

  • KPC Pharmaceuticals, Inc.
  • Shanghai Fosun Pharmaceutical Industrial Development Company Limited
  • Sanofi
  • Desano Holdings Ltd.
  • Calyx Chemicals and Pharmaceuticals Limited
  • Mylan N.V.
  • Novartis AG
  • Denk Pharma GmbH & Co. KG
  • Hovid Berhad
  • Ipca Laboratories Limited
  • Cipla Limited
  • Aspen Pharmacare Holdings Limited
図表

List of Tables

  • Table 1 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Region (2016-2026) (US $MN)
  • Table 2 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 3 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 4 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 5 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 6 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 7 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 8 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
  • Table 9 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
  • Table 10 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 11 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 12 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 13 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 14 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 15 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 16 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
  • Table 17 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
  • Table 18 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 19 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 20 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 21 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 22 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 23 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 24 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
  • Table 25 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
  • Table 26 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 27 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 28 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 29 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 30 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 31 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 32 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
  • Table 33 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
  • Table 34 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 35 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 36 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 37 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 38 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 39 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 40 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
  • Table 41 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
  • Table 42 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 43 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 44 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 45 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 46 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 47 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 48 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
目次

According to Stratistics MRC, the Global Artemisinin Combination Therapy (ACT) market is accounted for $338.80 billion in 2017 and is expected to reach $830.98 billion by 2026 growing at a CAGR of 10.5% during the forecast period. Rising pipeline for new anti-malarial drugs, growing demand for artemisinin combination therapy (ACT) and increasing government initiatives are few factors propelling for the growth of the market. However, limited number of manufacturers globally acts as a hindrance for the market growth.

Based on type, Artesunate-Mefloquine is a lucrative market for Artemisinin Combination Therapy (ACT) due to its quick spread of resistance, mediated mainly by a raise in copy number and expression of the P. falciparum multi-drug resistance (MDR) gene. This improves bioavailability and reduces vomiting. There is no formulation of mefloquine for children. Regardless of earlier restrictions there is no cause to withhold mefloquine for young children. Limited information recommends that mefloquine is perhaps secure in pregnancy.

By geography, Middle East and Africa held the largest market share in the artemisinin combination therapy owing to have large number of production base of artemisinin herbs and growing demand in malaria endemic countries which are contributing to the expansion of the market in MEA. Though African countries, where the occurrence of malaria is high, so they have amplified malaria control strategies, efficient treatment and control, but it still presents a huge logistical difficulty. As numerous at-risk people survive in extreme poverty in isolated areas, WHO and other organizations are working on completely eradicating it in Africa and thus, over the coming years, the adoption rate of ACT is further expected to boost.

Some of the key players profiled in the Artemisinin Combination Therapy (ACT) market include KPC Pharmaceuticals, Inc., Shanghai Fosun Pharmaceutical Industrial Development Company Limited, Sanofi, Desano Holdings Ltd., Calyx Chemicals and Pharmaceuticals Limited, Mylan N.V., Novartis AG, Denk Pharma GmbH & Co. KG, Hovid Berhad, Ipca Laboratories Limited, Cipla Limited and Aspen Pharmacare Holdings Limited.

Types Covered:

  • Artesunate-Sulfadoxine-Pyrimethamine
  • Artesunate-Mefloquine
  • Artesunate-Pyronaridine
  • Artemether-Lumefantrine
  • Artesunate-Amodiaquine
  • Dihydroartemisinin-Piperaquine

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Artemisinin Combination Therapy (ACT) Market, By Type

  • 5.1 Introduction
  • 5.2 Artesunate-Sulfadoxine-Pyrimethamine
  • 5.3 Artesunate-Mefloquine
  • 5.4 Artesunate-Pyronaridine
  • 5.5 Artemether-Lumefantrine
  • 5.6 Artesunate-Amodiaquine
  • 5.7 Dihydroartemisinin-Piperaquine

6 Global Artemisinin Combination Therapy (ACT) Market, By Geography

  • 6.1 Introduction
  • 6.2 North America
    • 6.2.1 US
    • 6.2.2 Canada
    • 6.2.3 Mexico
  • 6.3 Europe
    • 6.3.1 Germany
    • 6.3.2 UK
    • 6.3.3 Italy
    • 6.3.4 France
    • 6.3.5 Spain
    • 6.3.6 Rest of Europe
  • 6.4 Asia Pacific
    • 6.4.1 Japan
    • 6.4.2 China
    • 6.4.3 India
    • 6.4.4 Australia
    • 6.4.5 New Zealand
    • 6.4.6 South Korea
    • 6.4.7 Rest of Asia Pacific
  • 6.5 South America
    • 6.5.1 Argentina
    • 6.5.2 Brazil
    • 6.5.3 Chile
    • 6.5.4 Rest of South America
  • 6.6 Middle East & Africa
    • 6.6.1 Saudi Arabia
    • 6.6.2 UAE
    • 6.6.3 Qatar
    • 6.6.4 South Africa
    • 6.6.5 Rest of Middle East & Africa

7 Key Developments

  • 7.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 7.2 Acquisitions & Mergers
  • 7.3 New Product Launch
  • 7.4 Expansions
  • 7.5 Other Key Strategies

8 Company Profiling

  • 8.1 KPC Pharmaceuticals, Inc.
  • 8.2 Shanghai Fosun Pharmaceutical Industrial Development Company Limited
  • 8.3 Sanofi
  • 8.4 Desano Holdings Ltd.
  • 8.5 Calyx Chemicals and Pharmaceuticals Limited
  • 8.6 Mylan N.V.
  • 8.7 Novartis AG
  • 8.8 Denk Pharma GmbH & Co. KG
  • 8.9 Hovid Berhad
  • 8.10 Ipca Laboratories Limited
  • 8.11 Cipla Limited
  • 8.12 Aspen Pharmacare Holdings Limited
Back to Top